These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 837649)

  • 1. Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide.
    Williams RL; Blaschke TF; Meffin PJ; Melmon KL; Rowland M
    Clin Pharmacol Ther; 1977 Mar; 21(3):301-9. PubMed ID: 837649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.
    Wing LM; Miners JO
    Br J Clin Pharmacol; 1985 Nov; 20(5):482-5. PubMed ID: 3878154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of drug-drug interactions in sheep: tolbutamide and sulfadimethoxine.
    Thiessen JJ; Rowland M
    J Pharm Sci; 1977 Aug; 66(8):1063-70. PubMed ID: 894490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of total plasma concentration and age on tolbutamide plasma protein binding.
    Adir J; Miller AK; Vestal RE
    Clin Pharmacol Ther; 1982 Apr; 31(4):488-93. PubMed ID: 7060330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and metabolic elimination of tolbutamide in female rats: Comparison with male rats.
    Fukuno S; Nagai K; Horii A; Yamamoto K; Konishi H
    Biopharm Drug Dispos; 2018 Jul; 39(7):321-327. PubMed ID: 29978919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenidap sodium does not alter the clearance or plasma protein binding of tolbutamide in healthy male volunteers.
    Wilner KD; Gardner MJ
    Br J Clin Pharmacol; 1995; 39 Suppl 1(Suppl 1):39S-42S. PubMed ID: 7547093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination.
    Miners JO; Foenander T; Wanwimolruk S; Gallus AS; Birkett DJ
    Eur J Clin Pharmacol; 1982; 22(4):321-6. PubMed ID: 7106168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apparent volumes of distribution and drug binding to plasma proteins and tissues.
    Gibaldi M; McNamara PJ
    Eur J Clin Pharmacol; 1978 Jul; 13(5):373-80. PubMed ID: 668796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of quinidine related to plasma protein binding in man.
    Fremstad D; Nilsen OG; Storstein L; Amlie J; Jacobsen S
    Eur J Clin Pharmacol; 1979 Apr; 15(3):187-92. PubMed ID: 456401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of peritoneal dialysis of tolbutamide in rats under conditions of the plasma unbound fraction being increased.
    Makita T; Aiba T; Izuwa Y; Komori Y; Kawasaki H; Kurosaki Y
    Biopharm Drug Dispos; 2009 Jan; 30(1):1-8. PubMed ID: 19148953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unaltered metabolism of antipyrine and tolbutamide in fasting man.
    Reidenberg MM; Vesell ES
    Clin Pharmacol Ther; 1975 Jun; 17(6):650-6. PubMed ID: 1139856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin.
    Williams RL; Schary WL; Blaschke TF; Meffin PJ; Melmon KL; Rowland M
    Clin Pharmacol Ther; 1976 Jul; 20(1):90-7. PubMed ID: 1277729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein binding and hepatic clearance: studies with tolbutamide, a drug of low intrinsic clearance, in the isolated perfused rat liver preparation.
    Schary WL; Rowland M
    J Pharmacokinet Biopharm; 1983 Jun; 11(3):225-43. PubMed ID: 6644551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of inhibition of tolbutamide hydroxylation by cimetidine in man.
    Stockley C; Keal J; Rolan P; Bochner F; Somogyi A
    Eur J Clin Pharmacol; 1986; 31(2):235-7. PubMed ID: 3803421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma protein binding of diazepam and tolbutamide in chronic alcoholics.
    Thiessen JJ; Sellers EM; Denbeigh P; Dolman L
    J Clin Pharmacol; 1976 Jul; 16(7):345-51. PubMed ID: 947967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic analysis of tolbutamide-sulfonamide interaction in rabbits based on clearance concept. Prediction of species difference from in vitro plasma protein binding and metabolism.
    Sugita O; Sawada Y; Sugiyama Y; Iga T; Hanano M
    Drug Metab Dispos; 1984; 12(1):131-8. PubMed ID: 6141904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data.
    Ashforth EI; Carlile DJ; Chenery R; Houston JB
    J Pharmacol Exp Ther; 1995 Aug; 274(2):761-6. PubMed ID: 7636740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic analysis of the interaction between dicoumarol and tolbutamide in man.
    Jähnchen E; Meinertz T; Gilfrich HJ; Groth U
    Eur J Clin Pharmacol; 1976 Sep; 10(5):349-56. PubMed ID: 61862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of plasma protein binding on quinidine kinetics in the rabbit.
    Guentert TW; Oie S
    J Pharmacol Exp Ther; 1980 Oct; 215(1):165-71. PubMed ID: 7452481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: lidocaine and indocyanine green.
    Williams RL; Blaschke TF; Meffin PJ; Melmon KL; Rowland M
    Clin Pharmacol Ther; 1976 Sep; 20(3):290-9. PubMed ID: 954351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.